Abstract

Cardiac resynchronization therapy (CRT) markedly reduces morbidity and mortality in patients with heart failure and prolonged QRS duration. Landmark trials have included over 4000 patients based on their electrocardiogram. A few small, observational, non-randomized, single centre studies of short duration have suggested that echocardiographic measurement of mechanical dyssynchrony may better identify patients likely to benefit from CRT. We objectively review the meaning and measurement of electrical and mechanical dyssynchrony, the strengths and weaknesses of echocardiographic indices of dyssynchrony, and the controversial issue of predicting response to treatment. We conclude that proposals to alter current guidelines for patient selection, and include echocardiography, are misguided. Echocardiographic assessment will only become credible and applicable to clinical practice once used to select patients for large prospective randomized trials which show an improvement in clinical outcome.

Introduction

Cardiac resynchronization therapy (CRT) improves functional status and reduces hospitalizations and mortality in patients with heart failure (HF). In the pivotal large randomized trials, patients were selected on the basis of three main criteria: impaired functional status (New York Heart Association class III or IV), reduced left ventricular (LV) ejection fraction (≤0.35), and prolonged QRS duration (≥120 ms). The latter was considered a marker of underlying ventricular dyssynchrony (so-called ‘electrical dyssynchrony’) (Table 1). Consequently, international guidelines recommend CRT based on the electrocardiographic (ECG) inclusion criteria in those trials.1

Table 1

Inclusion criteria and outcomes of CRT trials

StudynDesignFollow-up (months)QRS duration (ms)LVEDD (mm)EchoLVEF (%)NYHA classSR/AFICDEndpoints

PATH-CHF2141Cross-over1≥120No cut-offNoNo cut-offIII, IVSRNo6MWT+44 m; P<0.001MLHFQ−19.3; P<0.001Peak VO2+1.8; P<0.001
PATH-CHF II7086Cross-over3≥120No cut-offNo≤30II–IVSRYes6MWT+47 m; P=0.024MLHFQ−8.1; P=0.004Peak VO2 +2.5; P<0.001
MUSTIC-SR1948Cross-over3>150>60No<35IIISRNo6MWT+73 m; P<0.001MLHFQ−13.6; P<0.001Peak VO2 +1.2; P=0.029
MUSTIC-AF7137Cross-over3>200 paced>60No<35IIIAFNo6MWT+32 m; P=0.05MLHFQ−4.3; P=0.11Peak VO2 +1.7; P=0.04
MIRACLE2453Parallel6≥130≥55No≤35III, IVSRNo6MWT+29 m; P=0.005MLHFQ−9.0; P=0.001NYHA; P<0.001
MIRACLE-ICD72369Parallel6≥130≥55No≤35III, IVSRYes6MWT+2 m; P=0.36MLHFQ−6.5; P=0.02NYHA; P=0.007
MIRACLE-ICD II73186Parallel6≥130≥55No≤35IISRYes6MWT+5 m; P=0.59MLHFQ−2.6; P=0.49Peak VO2 +0.3; P=0.87
CONTAK-CD74490Parallel6≥120No cut-offNo≤35II–IVSRYes6MWT+20 m; P=0.043MLHFQ−2; P=0.39Peak VO2 +0.8; P=0.03
COMPANION221520Parallel16.2 (median)≥120≥60No≤35III, IVSRYesDeath, admission HR 0.81; P=0.015Death HR 0.76; P=0.06HF death, admission HR 0.66; P=0.002
CARE-HF23813Parallel29.4 (mean)≥150; ≥120+echo30 height indexedYes (n=92)≤35III, IVSRNoDeath or MACE HR 0.63; P<0.001Death HR 0.64; P=0.002HF admission HR 0.48; P<0.001
StudynDesignFollow-up (months)QRS duration (ms)LVEDD (mm)EchoLVEF (%)NYHA classSR/AFICDEndpoints

PATH-CHF2141Cross-over1≥120No cut-offNoNo cut-offIII, IVSRNo6MWT+44 m; P<0.001MLHFQ−19.3; P<0.001Peak VO2+1.8; P<0.001
PATH-CHF II7086Cross-over3≥120No cut-offNo≤30II–IVSRYes6MWT+47 m; P=0.024MLHFQ−8.1; P=0.004Peak VO2 +2.5; P<0.001
MUSTIC-SR1948Cross-over3>150>60No<35IIISRNo6MWT+73 m; P<0.001MLHFQ−13.6; P<0.001Peak VO2 +1.2; P=0.029
MUSTIC-AF7137Cross-over3>200 paced>60No<35IIIAFNo6MWT+32 m; P=0.05MLHFQ−4.3; P=0.11Peak VO2 +1.7; P=0.04
MIRACLE2453Parallel6≥130≥55No≤35III, IVSRNo6MWT+29 m; P=0.005MLHFQ−9.0; P=0.001NYHA; P<0.001
MIRACLE-ICD72369Parallel6≥130≥55No≤35III, IVSRYes6MWT+2 m; P=0.36MLHFQ−6.5; P=0.02NYHA; P=0.007
MIRACLE-ICD II73186Parallel6≥130≥55No≤35IISRYes6MWT+5 m; P=0.59MLHFQ−2.6; P=0.49Peak VO2 +0.3; P=0.87
CONTAK-CD74490Parallel6≥120No cut-offNo≤35II–IVSRYes6MWT+20 m; P=0.043MLHFQ−2; P=0.39Peak VO2 +0.8; P=0.03
COMPANION221520Parallel16.2 (median)≥120≥60No≤35III, IVSRYesDeath, admission HR 0.81; P=0.015Death HR 0.76; P=0.06HF death, admission HR 0.66; P=0.002
CARE-HF23813Parallel29.4 (mean)≥150; ≥120+echo30 height indexedYes (n=92)≤35III, IVSRNoDeath or MACE HR 0.63; P<0.001Death HR 0.64; P=0.002HF admission HR 0.48; P<0.001

6MWT, 6 minute walk test; AF, atrial fibrillation; ICD, implantable cardioverter defibrillator; LVEDD, left ventricular end diastolic diameter; MACE, major adverse cardiovascular event; MLHFQ, Minnesota Living with Heart Failure Questionnaire; SR, sinus rhythm; VO2, oxygen consumption (mL/min/kg).

Table 1

Inclusion criteria and outcomes of CRT trials

StudynDesignFollow-up (months)QRS duration (ms)LVEDD (mm)EchoLVEF (%)NYHA classSR/AFICDEndpoints

PATH-CHF2141Cross-over1≥120No cut-offNoNo cut-offIII, IVSRNo6MWT+44 m; P<0.001MLHFQ−19.3; P<0.001Peak VO2+1.8; P<0.001
PATH-CHF II7086Cross-over3≥120No cut-offNo≤30II–IVSRYes6MWT+47 m; P=0.024MLHFQ−8.1; P=0.004Peak VO2 +2.5; P<0.001
MUSTIC-SR1948Cross-over3>150>60No<35IIISRNo6MWT+73 m; P<0.001MLHFQ−13.6; P<0.001Peak VO2 +1.2; P=0.029
MUSTIC-AF7137Cross-over3>200 paced>60No<35IIIAFNo6MWT+32 m; P=0.05MLHFQ−4.3; P=0.11Peak VO2 +1.7; P=0.04
MIRACLE2453Parallel6≥130≥55No≤35III, IVSRNo6MWT+29 m; P=0.005MLHFQ−9.0; P=0.001NYHA; P<0.001
MIRACLE-ICD72369Parallel6≥130≥55No≤35III, IVSRYes6MWT+2 m; P=0.36MLHFQ−6.5; P=0.02NYHA; P=0.007
MIRACLE-ICD II73186Parallel6≥130≥55No≤35IISRYes6MWT+5 m; P=0.59MLHFQ−2.6; P=0.49Peak VO2 +0.3; P=0.87
CONTAK-CD74490Parallel6≥120No cut-offNo≤35II–IVSRYes6MWT+20 m; P=0.043MLHFQ−2; P=0.39Peak VO2 +0.8; P=0.03
COMPANION221520Parallel16.2 (median)≥120≥60No≤35III, IVSRYesDeath, admission HR 0.81; P=0.015Death HR 0.76; P=0.06HF death, admission HR 0.66; P=0.002
CARE-HF23813Parallel29.4 (mean)≥150; ≥120+echo30 height indexedYes (n=92)≤35III, IVSRNoDeath or MACE HR 0.63; P<0.001Death HR 0.64; P=0.002HF admission HR 0.48; P<0.001
StudynDesignFollow-up (months)QRS duration (ms)LVEDD (mm)EchoLVEF (%)NYHA classSR/AFICDEndpoints

PATH-CHF2141Cross-over1≥120No cut-offNoNo cut-offIII, IVSRNo6MWT+44 m; P<0.001MLHFQ−19.3; P<0.001Peak VO2+1.8; P<0.001
PATH-CHF II7086Cross-over3≥120No cut-offNo≤30II–IVSRYes6MWT+47 m; P=0.024MLHFQ−8.1; P=0.004Peak VO2 +2.5; P<0.001
MUSTIC-SR1948Cross-over3>150>60No<35IIISRNo6MWT+73 m; P<0.001MLHFQ−13.6; P<0.001Peak VO2 +1.2; P=0.029
MUSTIC-AF7137Cross-over3>200 paced>60No<35IIIAFNo6MWT+32 m; P=0.05MLHFQ−4.3; P=0.11Peak VO2 +1.7; P=0.04
MIRACLE2453Parallel6≥130≥55No≤35III, IVSRNo6MWT+29 m; P=0.005MLHFQ−9.0; P=0.001NYHA; P<0.001
MIRACLE-ICD72369Parallel6≥130≥55No≤35III, IVSRYes6MWT+2 m; P=0.36MLHFQ−6.5; P=0.02NYHA; P=0.007
MIRACLE-ICD II73186Parallel6≥130≥55No≤35IISRYes6MWT+5 m; P=0.59MLHFQ−2.6; P=0.49Peak VO2 +0.3; P=0.87
CONTAK-CD74490Parallel6≥120No cut-offNo≤35II–IVSRYes6MWT+20 m; P=0.043MLHFQ−2; P=0.39Peak VO2 +0.8; P=0.03
COMPANION221520Parallel16.2 (median)≥120≥60No≤35III, IVSRYesDeath, admission HR 0.81; P=0.015Death HR 0.76; P=0.06HF death, admission HR 0.66; P=0.002
CARE-HF23813Parallel29.4 (mean)≥150; ≥120+echo30 height indexedYes (n=92)≤35III, IVSRNoDeath or MACE HR 0.63; P<0.001Death HR 0.64; P=0.002HF admission HR 0.48; P<0.001

6MWT, 6 minute walk test; AF, atrial fibrillation; ICD, implantable cardioverter defibrillator; LVEDD, left ventricular end diastolic diameter; MACE, major adverse cardiovascular event; MLHFQ, Minnesota Living with Heart Failure Questionnaire; SR, sinus rhythm; VO2, oxygen consumption (mL/min/kg).

Some have stated that around one-third of patients appear not to improve clinically or exhibit favourable echocardiographic remodelling (so-called ‘non-responders’).2,3 It has been proposed that echocardiography may better identify those likely to respond to treatment by measuring actual mechanical dyssynchrony.4 If correct, this alternate approach to patient selection has two important clinical consequences. First, non-responders with a broad QRS would be spared an ineffective and invasive procedure, with resultant cost savings to healthcare providers. Conversely, patients with mechanical dyssynchrony but a narrow QRS complex, who were excluded from the landmark clinical trials, may benefit from CRT.

We review the meaning and measurement of electrical and mechanical dyssynchrony, the strengths and weaknesses of echocardiographic indices of dyssynchrony, and the controversial issue of predicting response to treatment. How valid is the concept of ‘responders’ vs. ‘non-responders’? Should patients eligible for treatment based on inclusion criteria for clinical trials be excluded from that treatment in clinical practice? Why is such an approach advocated for devices but not for drug therapy?

Electrical dyssynchrony

What is electrical dyssynchrony?

The QRS complex represents the vectorial sum of electrical forces generated by myocardial masses over time. Normal electrical activation propagates as a uniform high-velocity wavefront through the myocardial Purkinje network. In damaged myocardium, altered conduction properties impair the velocity and direction of electrical propagation. Abnormal ventricular depolarization, manifesting as QRS prolongation, generates regions of both early and delayed ventricular contraction. The delayed segments accommodate contractile force and volume, reducing systolic function.

Why is electrical dyssynchrony important?

A direct relationship exists between QRS duration and ejection fraction.5–7 Prevalence of bundle branch block (BBB) varies from around 20% in the general HF population5,6 to 35% among patients with more severely impaired systolic function.7,8 BBB is a powerful independent predictor of mortality,8 with no evidence of any threshold effect at 120 ms.9 QRS duration has been the principal entry point to all major CRT trials to date (Table 1). National guidelines recommend CRT in patients with medically refractory, symptomatic (NYHA III/IV) HF, with prolonged QRS duration ≥120 ms, and ejection fraction ≤35%.1 Simultaneous biventricular (BiV) pacing resynchronizes both intra- and interventricular contractions. The result is haemodynamic improvement,10–13 reduced mitral regurgitation,14 and reversal of maladaptive remodelling.15–18 CRT improves symptoms, quality of life and functional class,2 increases exercise tolerance,2,19–21 and reduces hospitalizations and mortality.22,23

Baseline QRS duration consistently fails to predict response (Tables 2 and 7). However, change in QRS duration (ΔQRS) following CRT differs significantly between responders and non-responders in a number of studies.24–27 This correlation between QRS narrowing and clinical efficacy suggests that after LV lead implantation, positioning the RV lead to produce maximal QRS shortening may improve resynchronization.27 In a recent study, ΔQRS was an independent predictor of response after multivariate adjustment. The RV lead was positioned for maximum reduction in QRS duration at the apex, septum, anterior wall, or RV outflow tract, guided by intra-operative biventricular pace mapping.24

Table 2

Studies defining change in QRS duration following CRT

ReferencenInclusion QRS duration (ms)Follow-up (months)Response criteriaNon-responders (%)QRS responders vs. non-responders (ms)
BaselineΔQRS

Lecoq et al.24139>1506Survival, and HF hospitalization, and NYHA≥1 class, or peak VO2≥10% or 6-min walk≥10%28192 vs. 180; P=0.01837 vs. 11; P<0.001
Pitzalis et al.2560>13014Survival, and heart failure hospitalization27168 vs. 179; P=NS45 vs. 31; P<0.05
Bax et al.2685≥1206NYHA≥1 class, and 6-min walk≥25%26174 vs. 171; P=NS32 vs. 6; P<0.01
Molhoek et al.7561>1206NYHA≥1 class26179 vs. 171; P=NS29 vs. 11; P=0.07
Alonso et al.2726>1206Survival, and NYHA≥1 class, and peak VO2≥10%27179 vs. 176; P=NS23 vs. 4; P=0.04
Penicka et al.5849≥1306≥25% LVEF45190 vs. 171; P<0.0138 vs. 17; —
Pitzalis et al.3720≥1401≥15% LVESV40173 vs. 164; P=NS21 vs. 22; P=NS
Yu et al.5530>1403≥15% LVESV43166 vs. 150; P=NS24 vs. 19; P=NS
ReferencenInclusion QRS duration (ms)Follow-up (months)Response criteriaNon-responders (%)QRS responders vs. non-responders (ms)
BaselineΔQRS

Lecoq et al.24139>1506Survival, and HF hospitalization, and NYHA≥1 class, or peak VO2≥10% or 6-min walk≥10%28192 vs. 180; P=0.01837 vs. 11; P<0.001
Pitzalis et al.2560>13014Survival, and heart failure hospitalization27168 vs. 179; P=NS45 vs. 31; P<0.05
Bax et al.2685≥1206NYHA≥1 class, and 6-min walk≥25%26174 vs. 171; P=NS32 vs. 6; P<0.01
Molhoek et al.7561>1206NYHA≥1 class26179 vs. 171; P=NS29 vs. 11; P=0.07
Alonso et al.2726>1206Survival, and NYHA≥1 class, and peak VO2≥10%27179 vs. 176; P=NS23 vs. 4; P=0.04
Penicka et al.5849≥1306≥25% LVEF45190 vs. 171; P<0.0138 vs. 17; —
Pitzalis et al.3720≥1401≥15% LVESV40173 vs. 164; P=NS21 vs. 22; P=NS
Yu et al.5530>1403≥15% LVESV43166 vs. 150; P=NS24 vs. 19; P=NS

VO2, oxygen consumption.

Table 2

Studies defining change in QRS duration following CRT

ReferencenInclusion QRS duration (ms)Follow-up (months)Response criteriaNon-responders (%)QRS responders vs. non-responders (ms)
BaselineΔQRS

Lecoq et al.24139>1506Survival, and HF hospitalization, and NYHA≥1 class, or peak VO2≥10% or 6-min walk≥10%28192 vs. 180; P=0.01837 vs. 11; P<0.001
Pitzalis et al.2560>13014Survival, and heart failure hospitalization27168 vs. 179; P=NS45 vs. 31; P<0.05
Bax et al.2685≥1206NYHA≥1 class, and 6-min walk≥25%26174 vs. 171; P=NS32 vs. 6; P<0.01
Molhoek et al.7561>1206NYHA≥1 class26179 vs. 171; P=NS29 vs. 11; P=0.07
Alonso et al.2726>1206Survival, and NYHA≥1 class, and peak VO2≥10%27179 vs. 176; P=NS23 vs. 4; P=0.04
Penicka et al.5849≥1306≥25% LVEF45190 vs. 171; P<0.0138 vs. 17; —
Pitzalis et al.3720≥1401≥15% LVESV40173 vs. 164; P=NS21 vs. 22; P=NS
Yu et al.5530>1403≥15% LVESV43166 vs. 150; P=NS24 vs. 19; P=NS
ReferencenInclusion QRS duration (ms)Follow-up (months)Response criteriaNon-responders (%)QRS responders vs. non-responders (ms)
BaselineΔQRS

Lecoq et al.24139>1506Survival, and HF hospitalization, and NYHA≥1 class, or peak VO2≥10% or 6-min walk≥10%28192 vs. 180; P=0.01837 vs. 11; P<0.001
Pitzalis et al.2560>13014Survival, and heart failure hospitalization27168 vs. 179; P=NS45 vs. 31; P<0.05
Bax et al.2685≥1206NYHA≥1 class, and 6-min walk≥25%26174 vs. 171; P=NS32 vs. 6; P<0.01
Molhoek et al.7561>1206NYHA≥1 class26179 vs. 171; P=NS29 vs. 11; P=0.07
Alonso et al.2726>1206Survival, and NYHA≥1 class, and peak VO2≥10%27179 vs. 176; P=NS23 vs. 4; P=0.04
Penicka et al.5849≥1306≥25% LVEF45190 vs. 171; P<0.0138 vs. 17; —
Pitzalis et al.3720≥1401≥15% LVESV40173 vs. 164; P=NS21 vs. 22; P=NS
Yu et al.5530>1403≥15% LVESV43166 vs. 150; P=NS24 vs. 19; P=NS

VO2, oxygen consumption.

Mechanical dyssynchrony

What is mechanical dyssynchrony?

Mechanical dyssynchrony may be considered in terms of inter- and intraventricular components. Interventricular dyssynchrony refers to delayed activation of the LV relative to the right ventricle. Intraventricular dyssynchrony refers to delayed activation of one LV region relative to another. Correction of intraventricular delay frequently simultaneously improves interventricular delay through ventricular interdependence. CRT aims to correct both aspects of mechanical dyssynchrony.

Why is mechanical dyssynchrony important?

Baseline QRS duration consistently fails to predict response (Tables 2 and 7). The ECG is unable to convey the presence and severity of electrical delay in all ventricular segments and correlates particularly poorly with disturbance of distal conduction tissue. QRS morphology and duration are only influenced by significant myocardial masses. Regional changes represented by small vectors are inadequately displayed. In failing myocardium, heterogeneous interstitial fibrosis occurs with localized rearrangement of extracellular matrix and myocytes. Consequently, normal depolarization is replaced by a diffuse activation wavefront travelling throughout the myocardial wall.28 This disorganized depolarization generates abnormal regional loading conditions, inducing further localized fibrosis and hypertrophy with consequent mechanical dyssynchrony.

Although coupling of electrical activation and mechanical contraction remains incompletely defined, there is convincing evidence of electromechanical dissociation. QRS duration has no correlation with intraventricular dyssynchrony (Table 3) and only a limited relationship with interventricular dyssynchrony (Table 4). Regional delays in time to peak systolic velocity (Ts) occur in addition to delays in isovolumic contraction, suggesting further mechanical limitation occurs after electrical activation.29 In myocardial ischaemia, impaired regional contractility and wall motion abnormalities frequently produce mechanical dyssynchrony without disturbing electrical conduction. Haemodynamic studies indicate both BiV and LV pacing similarly augment systolic function regardless of different electrical activation.10,11 In fact, cardiac output improves during LV pacing despite a significant increase in QRS duration.30,31 This suggests that benefit from CRT relates to improved mechanical rather than electrical coordination.

Table 3

Prevalence of intraventricular dyssynchrony

ParameternCut-off (ms) derivationCorrelation with QRSPrevalence of intraventricular dyssynchrony (%)
QRS<120 msQRS 120–150 msQRS>150 ms

Ts-2489060; selectedr=0.26; P=NS276070
Ts-2506460; selectedr=0.12; P=NS33
Ts-1249112100; selectedr=0.11; P=NS5173a
Ts-SD-124911232.6; 2 SD controlsr=0.12; P=NS4364a
EMD-83415850; 1 SD subjects305771
EMD-43310440; 2 SD controlsr=0.36; P=NS5684b89b
ParameternCut-off (ms) derivationCorrelation with QRSPrevalence of intraventricular dyssynchrony (%)
QRS<120 msQRS 120–150 msQRS>150 ms

Ts-2489060; selectedr=0.26; P=NS276070
Ts-2506460; selectedr=0.12; P=NS33
Ts-1249112100; selectedr=0.11; P=NS5173a
Ts-SD-124911232.6; 2 SD controlsr=0.12; P=NS4364a
EMD-83415850; 1 SD subjects305771
EMD-43310440; 2 SD controlsr=0.36; P=NS5684b89b

aPrevalence in patients with QRS>120 ms.

bIntermediate QRS 120–140 ms and wide QRS>140 ms.

Table 3

Prevalence of intraventricular dyssynchrony

ParameternCut-off (ms) derivationCorrelation with QRSPrevalence of intraventricular dyssynchrony (%)
QRS<120 msQRS 120–150 msQRS>150 ms

Ts-2489060; selectedr=0.26; P=NS276070
Ts-2506460; selectedr=0.12; P=NS33
Ts-1249112100; selectedr=0.11; P=NS5173a
Ts-SD-124911232.6; 2 SD controlsr=0.12; P=NS4364a
EMD-83415850; 1 SD subjects305771
EMD-43310440; 2 SD controlsr=0.36; P=NS5684b89b
ParameternCut-off (ms) derivationCorrelation with QRSPrevalence of intraventricular dyssynchrony (%)
QRS<120 msQRS 120–150 msQRS>150 ms

Ts-2489060; selectedr=0.26; P=NS276070
Ts-2506460; selectedr=0.12; P=NS33
Ts-1249112100; selectedr=0.11; P=NS5173a
Ts-SD-124911232.6; 2 SD controlsr=0.12; P=NS4364a
EMD-83415850; 1 SD subjects305771
EMD-43310440; 2 SD controlsr=0.36; P=NS5684b89b

aPrevalence in patients with QRS>120 ms.

bIntermediate QRS 120–140 ms and wide QRS>140 ms.

Table 4

Prevalence of interventricular dyssynchrony

ParameternCut-off (ms) derivationCorrelation with QRSPrevalence of interventricular dyssynchrony (%)
QRS<120 msQRS 120–150 msQRS>150 ms

IVMD3415840; selectedr=0.66; P<0.001135272
IVMD513540; selectedr=0.86; P<0.0011844100
IVMD3310438; 2 SD controlsr=0.43; P<0.051234a46a
IVMD506450; selectedr=0.20; P=NS5
ParameternCut-off (ms) derivationCorrelation with QRSPrevalence of interventricular dyssynchrony (%)
QRS<120 msQRS 120–150 msQRS>150 ms

IVMD3415840; selectedr=0.66; P<0.001135272
IVMD513540; selectedr=0.86; P<0.0011844100
IVMD3310438; 2 SD controlsr=0.43; P<0.051234a46a
IVMD506450; selectedr=0.20; P=NS5

aIntermediate QRS 120–140 ms and wide QRS>140 ms.

Table 4

Prevalence of interventricular dyssynchrony

ParameternCut-off (ms) derivationCorrelation with QRSPrevalence of interventricular dyssynchrony (%)
QRS<120 msQRS 120–150 msQRS>150 ms

IVMD3415840; selectedr=0.66; P<0.001135272
IVMD513540; selectedr=0.86; P<0.0011844100
IVMD3310438; 2 SD controlsr=0.43; P<0.051234a46a
IVMD506450; selectedr=0.20; P=NS5
ParameternCut-off (ms) derivationCorrelation with QRSPrevalence of interventricular dyssynchrony (%)
QRS<120 msQRS 120–150 msQRS>150 ms

IVMD3415840; selectedr=0.66; P<0.001135272
IVMD513540; selectedr=0.86; P<0.0011844100
IVMD3310438; 2 SD controlsr=0.43; P<0.051234a46a
IVMD506450; selectedr=0.20; P=NS5

aIntermediate QRS 120–140 ms and wide QRS>140 ms.

How do we measure mechanical dyssynchrony?

Mechanical dyssynchrony may be assessed using conventional M-mode and Doppler echocardiography. Newer modalities include tissue Doppler imaging (TDI), strain rate imaging (SRI), and tissue synchronization imaging (TSI).

Interventricular dyssynchrony—conventional measurement

Interventricular mechanical delay (IVMD) is the difference in left and right ventricular pre-ejection intervals (LPEI and RPEI), measured from QRS onset to the beginning of aortic and pulmonary Doppler flow velocity curves respectively.32 An IVMD ≥40 ms, 2 SD above the mean of normal controls,33 represents interventricular dyssynchrony.32,34,35 The predictive utility is doubtful as multiple factors influence ventricular ejection, including changes in preload and afterload. In particular, prolonged RPEI in pulmonary hypertension or right ventricular dysfunction reduces IVMD and accuracy of assessment.34 Precisely identifying QRS onset may also be difficult, depending on QRS morphology and electrical trace clarity.

Intraventricular dyssynchrony—conventional measurement

Three conventional parameters of intraventricular dyssynchrony have been described. LPEI, the time interval between QRS onset and beginning of the aortic Doppler flow velocity curve,32 represents a complex interaction between ventricular contraction, preload, and afterload. A delay ≥140 ms is considered indicative of intraventricular dyssynchrony.32,35,36

Left lateral wall contraction (LLWC) suggests severe intraventricular dyssynchrony, defined as overlap of lateral wall contraction (using M-mode) and onset of diastolic filling (transmitral Doppler E-wave onset).32 Such co-existence of systole and diastole has a relatively high specificity but low sensitivity for identifying dyssynchrony.

Septal-to-posterior wall motion delay (SPWMD) measures time between maximal displacement of the septum and posterior wall on M-mode, with delay ≥130 ms considered significant intraventricular dyssynchrony.25,37,38 Several limitations exist. It is one-dimensional, comparing only two basal segments and neglecting the more frequently delayed lateral wall. Perpendicular M-mode sections of the proximal LV are often not possible. A calculated ‘anatomical’ M-mode lowers temporal resolution, whereas a skewed M-mode produces artefactual dyssynchrony by comparing segments at different longitudinal positions. Maximal septal or posterior wall endocardial excursion may be diminished and unclear in ischaemic populations, causing inaccurate assessment.38 Finally, the parameter reflects interventricular in addition to intraventricular dyssynchrony, as passive septal motion occurs due to right ventricular contraction.

Intraventricular dyssynchrony—TDI

TDI evaluates long-axis myocardial contraction in varying numbers of basal and mid-segments from apical 4, 3, and 2 chamber views. Either time to peak systolic velocity (Ts) or time to onset of systolic velocity (electromechanical delay, EMD) is measured relative to QRS onset. LV dyssynchrony is quantified either by the standard deviation of 12 segments (Ts-SD-12 or ‘dyssynchrony index’) or the maximal temporal difference between two (Ts-2, EMD-2) or more LV segments (e.g. Ts-6, Ts-12). Larger values of any parameter indicate more severe dyssynchrony.

Limitations of TDI are similar to conventional Doppler. Notably, the angle between the incident ultrasound beam and vector of myocardial motion influences measurements, and excessive gain causes spectral broadening and velocity overestimation. Pulsed wave TDI restricts sampling to a single position during each cardiac cycle. Comparison of multiple myocardial segments requires separate acquisitions in different cycles and is consequently limited by differences in heart rate, loading conditions, and respiration. By contrast, colour-coded TDI stores time velocity data superimposed on 2D cine loops, allowing rapid offline analysis of multiple segments simultaneously during the same cardiac cycle.

Intraventricular dyssynchrony—TSI

TSI software automatically measures Ts, colour codes delays, then superimposes colour mapping on real-time two-dimensional images. This allows immediate visual identification of regional delay, ranging from green (normal) to red (severe delay). Dedicated algorithms calculate dyssynchrony parameters involving all 12 segments within minutes, using three apical images.

Intraventricular dyssynchrony—SRI

TDI myocardial velocities are inherently inaccurate through incorporation of translational cardiac motion, rotation and ‘tethering’ contraction of adjacent segments. SRI reduces this by measuring localized myocardial deformation, thus differentiating between passive displacement and active systolic contraction. Unfortunately, low signal-to-noise ratio, artefacts, and complex data processing overshadow these theoretical merits,39,40 resulting in high intra- and interobserver variability (>16%)41,42 limiting reproducibility.

Which level of the ventricle should we assess for dyssynchrony?

The level of the ventricle at which to assess dyssynchrony is unclear. The LV base contains the largest myocardial mass and is potentially of most haemodynamic significance, especially with regard to mitral annular function and mitral regurgitation. However, in 158 consecutive patients the most delayed segments were mid-ventricular rather than basal in over two-thirds of cases.34 Dyssynchrony was also evenly distributed between basal and mid-ventricular segments in a second smaller study (n=25).43 Only basal dyssynchrony reduced acutely following CRT,43 although mid-ventricular improvement followed in the long-term.44 Basal rather than mid-level assessment may therefore be more important in predicting response to CRT.

Which walls of the ventricle should we assess for dyssynchrony?

The number of ventricular walls requiring assessment is equally unclear. A compromise is necessary between optimal detection of mechanical delay and feasibility of examining numerous segments in clinical practice. Measuring time between peak velocities in opposing basal septal and lateral segments, without utilizing QRS onset as a reference point, permits rapid analysis (septal to lateral delay, Ts-2).45 However, in four studies using different TDI parameters, the wall exhibiting maximal delay was lateral in just one-third of patients (30–35%),33,34,46,47 being mainly anterior, inferior, or posterior in the remaining two-thirds. Interrogation of only two segments may overlook a significant proportion of delayed myocardium, thus inadequately assessing dyssynchrony.

Prevalence and prognostic implications

In five studies,33,34,48–50 intraventricular dyssynchrony correlated poorly with QRS duration, being absent in around one-third of patients with an intermediate or wide QRS, and conversely present in many with a normal QRS duration (27–56%) (Table 3). The latter patients may potentially benefit from CRT. The difference in prevalence between studies almost certainly reflects the varying parameters.

By contrast, IVMD correlates significantly with QRS duration (Table 4),33,34,51 and is accordingly less common (5–18%) than intraventricular dyssynchrony in patients with a narrow QRS. Given this similarity to QRS duration, IVMD may have only limited additional value over the baseline ECG in predicting response to CRT. The only study examining the prognostic implications of mechanical dyssynchrony supports this notion.33 In that study (n=104), intraventricular dyssynchrony was the most powerful independent predictor of HF hospitalization [hazard ratio, HR 3.39 (95% CI: 2.12–6.05), P<0.001], independent of QRS duration and left ventricular ejection fraction (LVEF). However, while QRS width >140 ms was also an independent, although less potent risk factor [1.86 (1.11–3.21), P=0.022], interventricular dyssynchrony was not [1.18 (0.71–1.86), P=0.433].

Predicting response to therapy

Numerous parameters of intraventricular dyssynchrony have been suggested as predictors of potential responders to CRT (Table 5). These almost universally derive from retrospective, exploratory analyses of multiple measurements in small, single centre, non-randomized studies. In single centres, it is unclear whether patients from earlier studies were included in subsequent ones. Interpretation is confounded by varying definitions of both dyssynchrony and response. Direct comparisons between parameters are virtually absent. The duration of CRT was frequently only 3 months or less, arguably too short a period in which to identify measurable LV remodelling. The manuscripts are often not specific regarding whether or not consecutive patients were recruited and whether or not observers performing analysis were blinded. Many studies fail to define all standard statistical parameters of accuracy, which may be calculated from data presented using a standard ‘accuracy matrix’ (Table 6). Intra- and interobserver variability are frequently either not presented or quoted from previous separate studies.

Table 5

Design of studies investigating parameters predicting response to CRT

ReferencenFollow-up (months)Dyssynchrony parameterCut-off (ms)Cut-off derivationConsecutive patientsBlinded analysisObserver variability
Intra-Inter-

Pitzalis et al.37201SPWMD130ROC curve++0.960.91
Pitzalis et al.255114SPWMD130Previous study++
Marcus et al.38796SPWMD130Previous study+HighHigh
Bax et al.4525AcuteTs-260Selected++
Bax et al.26806Ts-465ROC curve++
Yu et al.55303Ts-SD-1232.62 SD normal controls<5%<5%
Notabartolo et al.57493Ts-6 (PVD)110Electrophysiology study+
Yu et al.42543Ts-SD-1231.4ROC curve3%5%
Penicka et al.58496EMD-360ROC curve++6.8%8.5%
EMD LV-RV566.1%7.2%
EMD Sum102
Dohi et al.6138AcuteSRI130Selected+2%4%
Gorcsan et al.6329AcuteTSI Ts-265ROC curve+4%6%
Yu et al.46563TSI Lat DelayROC curve4.2%5.9%
TSI Ts-SD-124634.4
TSI Ts-1246105
TSI Ts-SD-64634.5
TSI Ts-64678
ReferencenFollow-up (months)Dyssynchrony parameterCut-off (ms)Cut-off derivationConsecutive patientsBlinded analysisObserver variability
Intra-Inter-

Pitzalis et al.37201SPWMD130ROC curve++0.960.91
Pitzalis et al.255114SPWMD130Previous study++
Marcus et al.38796SPWMD130Previous study+HighHigh
Bax et al.4525AcuteTs-260Selected++
Bax et al.26806Ts-465ROC curve++
Yu et al.55303Ts-SD-1232.62 SD normal controls<5%<5%
Notabartolo et al.57493Ts-6 (PVD)110Electrophysiology study+
Yu et al.42543Ts-SD-1231.4ROC curve3%5%
Penicka et al.58496EMD-360ROC curve++6.8%8.5%
EMD LV-RV566.1%7.2%
EMD Sum102
Dohi et al.6138AcuteSRI130Selected+2%4%
Gorcsan et al.6329AcuteTSI Ts-265ROC curve+4%6%
Yu et al.46563TSI Lat DelayROC curve4.2%5.9%
TSI Ts-SD-124634.4
TSI Ts-1246105
TSI Ts-SD-64634.5
TSI Ts-64678

ROC, receiver operating characteristics.

Table 5

Design of studies investigating parameters predicting response to CRT

ReferencenFollow-up (months)Dyssynchrony parameterCut-off (ms)Cut-off derivationConsecutive patientsBlinded analysisObserver variability
Intra-Inter-

Pitzalis et al.37201SPWMD130ROC curve++0.960.91
Pitzalis et al.255114SPWMD130Previous study++
Marcus et al.38796SPWMD130Previous study+HighHigh
Bax et al.4525AcuteTs-260Selected++
Bax et al.26806Ts-465ROC curve++
Yu et al.55303Ts-SD-1232.62 SD normal controls<5%<5%
Notabartolo et al.57493Ts-6 (PVD)110Electrophysiology study+
Yu et al.42543Ts-SD-1231.4ROC curve3%5%
Penicka et al.58496EMD-360ROC curve++6.8%8.5%
EMD LV-RV566.1%7.2%
EMD Sum102
Dohi et al.6138AcuteSRI130Selected+2%4%
Gorcsan et al.6329AcuteTSI Ts-265ROC curve+4%6%
Yu et al.46563TSI Lat DelayROC curve4.2%5.9%
TSI Ts-SD-124634.4
TSI Ts-1246105
TSI Ts-SD-64634.5
TSI Ts-64678
ReferencenFollow-up (months)Dyssynchrony parameterCut-off (ms)Cut-off derivationConsecutive patientsBlinded analysisObserver variability
Intra-Inter-

Pitzalis et al.37201SPWMD130ROC curve++0.960.91
Pitzalis et al.255114SPWMD130Previous study++
Marcus et al.38796SPWMD130Previous study+HighHigh
Bax et al.4525AcuteTs-260Selected++
Bax et al.26806Ts-465ROC curve++
Yu et al.55303Ts-SD-1232.62 SD normal controls<5%<5%
Notabartolo et al.57493Ts-6 (PVD)110Electrophysiology study+
Yu et al.42543Ts-SD-1231.4ROC curve3%5%
Penicka et al.58496EMD-360ROC curve++6.8%8.5%
EMD LV-RV566.1%7.2%
EMD Sum102
Dohi et al.6138AcuteSRI130Selected+2%4%
Gorcsan et al.6329AcuteTSI Ts-265ROC curve+4%6%
Yu et al.46563TSI Lat DelayROC curve4.2%5.9%
TSI Ts-SD-124634.4
TSI Ts-1246105
TSI Ts-SD-64634.5
TSI Ts-64678

ROC, receiver operating characteristics.

Table 6

Accuracy matrix

DiseaseNo disease

Test +veTrue positive (TP)False positive (FP)Positive predictive value, PPV=TP/(TP+FP)
Test −veFalse negative (FN)True negative (TN)Negative predictive value, NPV=TN/(TN+FN)
Sensitivity, Sn=TP/(TP+FN)Specificity, SP=TN/(TN+FP)Accuracy=TP+TN/(TP+FP+TN+FN)
DiseaseNo disease

Test +veTrue positive (TP)False positive (FP)Positive predictive value, PPV=TP/(TP+FP)
Test −veFalse negative (FN)True negative (TN)Negative predictive value, NPV=TN/(TN+FN)
Sensitivity, Sn=TP/(TP+FN)Specificity, SP=TN/(TN+FP)Accuracy=TP+TN/(TP+FP+TN+FN)
Table 6

Accuracy matrix

DiseaseNo disease

Test +veTrue positive (TP)False positive (FP)Positive predictive value, PPV=TP/(TP+FP)
Test −veFalse negative (FN)True negative (TN)Negative predictive value, NPV=TN/(TN+FN)
Sensitivity, Sn=TP/(TP+FN)Specificity, SP=TN/(TN+FP)Accuracy=TP+TN/(TP+FP+TN+FN)
DiseaseNo disease

Test +veTrue positive (TP)False positive (FP)Positive predictive value, PPV=TP/(TP+FP)
Test −veFalse negative (FN)True negative (TN)Negative predictive value, NPV=TN/(TN+FN)
Sensitivity, Sn=TP/(TP+FN)Specificity, SP=TN/(TN+FP)Accuracy=TP+TN/(TP+FP+TN+FN)

Predicting response using conventional parameters

Pitzalis et al.37 initially demonstrated that SPWMD ≥130 ms, but not LPEI or IVMD, predicted reverse remodelling in 20 patients, with 63% specificity and 85% accuracy. Subsequently, in 60 patients with predominantly non-ischaemic cardiomyopathy, SPWMD ≥130 ms independently predicted long-term clinical improvement following CRT (median follow-up of 14 months).25 Despite defining response differently in the two studies, predictive accuracy (84 and 85%) and correlation between SPWMD and volumetric change were remarkably consistent (Table 7).

Table 7

Parameters of systolic dyssynchrony predicting response to CRT

Dyssynchrony parameterResponder definition% Non-respondersResponders vs. non-respondersCorrelationaAccuracy parameters
QRS (ms)PParameter (ms)PrPSnSpNPVPPVACC

SPWMD3715% LVESV40173 vs. 164NS246 vs. 110<0.0010.70<0.001100631008085
SPWMD255% LVEF530.69<0.0001927891b79b84b
SPWMD3815% LVESV77 vs. 590.630.100.4124666129
Ts-2455% LVEF32NS86 vs. 39<0.010.470.017768864b93b80b
Ts-426Clinicalc26174 vs. 171NS87 vs. 35<0.01808059b92b80b
Ts-42615% LVESV0.70<0.0019292
Ts-SD-125515% LVESV43166 vs. 150NS45.0 vs. 24.8<0.0010.76<0.001100100100100100
Ts-6 (PVD)57Clinicald24162 vs. 151NS264 vs. 1987833337867b
Ts-6 (PVD)5715% LVESV41166 vs. 150NS289 vs. 188<0.019755927680b
Ts-SD-124215% LVESV43155 vs. 147NS0.74<0.001967895b86b89b
EMD-35825% LVEF45190 vs. 171<0.0184 vs. 38<0.000185b77b81b82b82b
EMD LV-RV5884 vs. 43<0.000185b64b78b74b76b
EMD Sum58167 vs. 81<0.00010.73<0.0001967794b84b88
SRI6115% SV45164 vs. 169NS249 vs. 137<0.0050.93<0.0001958894b91b92b
TSI Ts-26315% SV48164 vs. 187NS161 vs. 18<0.0018710088b100b93b
TSI Lat Delay4615% LVESV46478859b82b66b
TSI Ts-SD-124647.3 vs. 29.2<0.0010.61<0.001878184b84b84b
TSI Ts-1246133.9 vs. 83.7<0.0010.60<0.001838581b86b84b
TSI Ts-SD-64642.9 vs. 26.6<0.0010.52<0.001709273b91b80b
TSI Ts-646105.2 vs. 65.5<0.0010.53<0.001737771b79b75b
Dyssynchrony parameterResponder definition% Non-respondersResponders vs. non-respondersCorrelationaAccuracy parameters
QRS (ms)PParameter (ms)PrPSnSpNPVPPVACC

SPWMD3715% LVESV40173 vs. 164NS246 vs. 110<0.0010.70<0.001100631008085
SPWMD255% LVEF530.69<0.0001927891b79b84b
SPWMD3815% LVESV77 vs. 590.630.100.4124666129
Ts-2455% LVEF32NS86 vs. 39<0.010.470.017768864b93b80b
Ts-426Clinicalc26174 vs. 171NS87 vs. 35<0.01808059b92b80b
Ts-42615% LVESV0.70<0.0019292
Ts-SD-125515% LVESV43166 vs. 150NS45.0 vs. 24.8<0.0010.76<0.001100100100100100
Ts-6 (PVD)57Clinicald24162 vs. 151NS264 vs. 1987833337867b
Ts-6 (PVD)5715% LVESV41166 vs. 150NS289 vs. 188<0.019755927680b
Ts-SD-124215% LVESV43155 vs. 147NS0.74<0.001967895b86b89b
EMD-35825% LVEF45190 vs. 171<0.0184 vs. 38<0.000185b77b81b82b82b
EMD LV-RV5884 vs. 43<0.000185b64b78b74b76b
EMD Sum58167 vs. 81<0.00010.73<0.0001967794b84b88
SRI6115% SV45164 vs. 169NS249 vs. 137<0.0050.93<0.0001958894b91b92b
TSI Ts-26315% SV48164 vs. 187NS161 vs. 18<0.0018710088b100b93b
TSI Lat Delay4615% LVESV46478859b82b66b
TSI Ts-SD-124647.3 vs. 29.2<0.0010.61<0.001878184b84b84b
TSI Ts-1246133.9 vs. 83.7<0.0010.60<0.001838581b86b84b
TSI Ts-SD-64642.9 vs. 26.6<0.0010.52<0.001709273b91b80b
TSI Ts-646105.2 vs. 65.5<0.0010.53<0.001737771b79b75b

ACC, accuracy; NPV, negative predictive value; PPV, positive predictive value; Sn, sensitivity; Sp, specificity; SV, stroke volume.

aCorrelation between dyssynchrony parameter and responder definition.

bAccuracy parameters calculated from data presented.

cClinical responder: improvement in NYHA≥1- and 6-min walking distance≥25%.

dClinical responder: two of three improvements: NYHA≥1; 6-min walking distance 50 m; quality of life score 15 points.

Table 7

Parameters of systolic dyssynchrony predicting response to CRT

Dyssynchrony parameterResponder definition% Non-respondersResponders vs. non-respondersCorrelationaAccuracy parameters
QRS (ms)PParameter (ms)PrPSnSpNPVPPVACC

SPWMD3715% LVESV40173 vs. 164NS246 vs. 110<0.0010.70<0.001100631008085
SPWMD255% LVEF530.69<0.0001927891b79b84b
SPWMD3815% LVESV77 vs. 590.630.100.4124666129
Ts-2455% LVEF32NS86 vs. 39<0.010.470.017768864b93b80b
Ts-426Clinicalc26174 vs. 171NS87 vs. 35<0.01808059b92b80b
Ts-42615% LVESV0.70<0.0019292
Ts-SD-125515% LVESV43166 vs. 150NS45.0 vs. 24.8<0.0010.76<0.001100100100100100
Ts-6 (PVD)57Clinicald24162 vs. 151NS264 vs. 1987833337867b
Ts-6 (PVD)5715% LVESV41166 vs. 150NS289 vs. 188<0.019755927680b
Ts-SD-124215% LVESV43155 vs. 147NS0.74<0.001967895b86b89b
EMD-35825% LVEF45190 vs. 171<0.0184 vs. 38<0.000185b77b81b82b82b
EMD LV-RV5884 vs. 43<0.000185b64b78b74b76b
EMD Sum58167 vs. 81<0.00010.73<0.0001967794b84b88
SRI6115% SV45164 vs. 169NS249 vs. 137<0.0050.93<0.0001958894b91b92b
TSI Ts-26315% SV48164 vs. 187NS161 vs. 18<0.0018710088b100b93b
TSI Lat Delay4615% LVESV46478859b82b66b
TSI Ts-SD-124647.3 vs. 29.2<0.0010.61<0.001878184b84b84b
TSI Ts-1246133.9 vs. 83.7<0.0010.60<0.001838581b86b84b
TSI Ts-SD-64642.9 vs. 26.6<0.0010.52<0.001709273b91b80b
TSI Ts-646105.2 vs. 65.5<0.0010.53<0.001737771b79b75b
Dyssynchrony parameterResponder definition% Non-respondersResponders vs. non-respondersCorrelationaAccuracy parameters
QRS (ms)PParameter (ms)PrPSnSpNPVPPVACC

SPWMD3715% LVESV40173 vs. 164NS246 vs. 110<0.0010.70<0.001100631008085
SPWMD255% LVEF530.69<0.0001927891b79b84b
SPWMD3815% LVESV77 vs. 590.630.100.4124666129
Ts-2455% LVEF32NS86 vs. 39<0.010.470.017768864b93b80b
Ts-426Clinicalc26174 vs. 171NS87 vs. 35<0.01808059b92b80b
Ts-42615% LVESV0.70<0.0019292
Ts-SD-125515% LVESV43166 vs. 150NS45.0 vs. 24.8<0.0010.76<0.001100100100100100
Ts-6 (PVD)57Clinicald24162 vs. 151NS264 vs. 1987833337867b
Ts-6 (PVD)5715% LVESV41166 vs. 150NS289 vs. 188<0.019755927680b
Ts-SD-124215% LVESV43155 vs. 147NS0.74<0.001967895b86b89b
EMD-35825% LVEF45190 vs. 171<0.0184 vs. 38<0.000185b77b81b82b82b
EMD LV-RV5884 vs. 43<0.000185b64b78b74b76b
EMD Sum58167 vs. 81<0.00010.73<0.0001967794b84b88
SRI6115% SV45164 vs. 169NS249 vs. 137<0.0050.93<0.0001958894b91b92b
TSI Ts-26315% SV48164 vs. 187NS161 vs. 18<0.0018710088b100b93b
TSI Lat Delay4615% LVESV46478859b82b66b
TSI Ts-SD-124647.3 vs. 29.2<0.0010.61<0.001878184b84b84b
TSI Ts-1246133.9 vs. 83.7<0.0010.60<0.001838581b86b84b
TSI Ts-SD-64642.9 vs. 26.6<0.0010.52<0.001709273b91b80b
TSI Ts-646105.2 vs. 65.5<0.0010.53<0.001737771b79b75b

ACC, accuracy; NPV, negative predictive value; PPV, positive predictive value; Sn, sensitivity; Sp, specificity; SV, stroke volume.

aCorrelation between dyssynchrony parameter and responder definition.

bAccuracy parameters calculated from data presented.

cClinical responder: improvement in NYHA≥1- and 6-min walking distance≥25%.

dClinical responder: two of three improvements: NYHA≥1; 6-min walking distance 50 m; quality of life score 15 points.

The clinical applicability and predictive value of SPWMD were strongly disputed in a recent retrospective analysis of the CONTAK-CD trial involving 79 patients with predominantly ischaemic cardiomyopathy (72%).38 SPWMD failed to correlate with left ventricular end systolic volume (LVESV) reduction, predicting response with just 24% sensitivity and 66% specificity. Feasibility of obtaining measurements and inter-observer reproducibility were very poor, with only 45% of patients having a definitive septal and posterior wall motion deflection.

Echocardiographic inclusion criteria in the Cardiac Resynchronization in Heart Failure (CARE-HF) study were in addition to, rather than replacing, intermediate QRS prolongation (120–150 ms).23 Ninety two (11%) patients were enrolled, requiring two of three echocardiographic indicators of dyssynchrony: LPEI >140 ms; IVMD >40 ms; or delayed LLWC. All three are relatively insensitive markers of dyssynchrony. Furthermore, by definition IVMD and LPEI are highly inter-dependent, the variance in the first largely attributable to the latter. Although the original report dichotomized results using a high cut-off for IVMD of 49.2 ms,23 subgroup analysis is unpublished.

Predicting response using TDI

The simplest tissue Doppler assessment, septal to lateral delay, was initially evaluated in 22 patients.52 Mean delay decreased from 97 to 28 ms immediately after CRT (P<0.05) and returned to baseline after discontinuing pacing. In a subsequent study,45 baseline delay was the only variable differentiating responders and non-responders (86 vs. 39 ms, P<0.01) and the only independent predictor of improved LVEF. Delay ≥60 ms predicted response with 80% overall accuracy.

Bax et al.26 then measured the maximal temporal difference between peak systolic velocities in four basal segments (anterior, inferior, septal, and lateral). In 85 patients, responders and non-responders were differentiated by baseline delays similar to the 2-segment model (87 vs. 35 ms, P<0.01). Dyssynchrony ≥65 ms yielded a sensitivity and specificity of 80% to predict clinical improvement and of 92% to predict reverse remodelling. Patients with dyssynchrony ≥65 ms had an excellent prognosis compared with those without (6 vs. 50% one year composite mortality or HF hospitalization, P<0.001).

Using a 12-segment model (6-basal, 6-mid), Yu et al.53 demonstrated improved synchronicity and reverse remodelling following CRT. LVEF improved from 28 to 40% after 3 months. Coordinated systolic contraction occurred through delay of early contracting segments, decreasing the standard deviation of Ts (Ts-SD-12) (29.3 vs. 37.7 ms, P<0.05). As observed by Bax et al.,52 improvements were pacing-dependent: withholding pacing immediately reduced LVEF and increased dyssynchrony (Ts-SD-12 41.1 vs. 29.3 ms, P<0.01). In a second study (n=33), Ts-SD-12 decreased similarly within 30 min of biventricular but not RV pacing, again correlating with acute volumetric improvements.54

Yu et al.55 examined predictors of reverse remodelling in 30 patients. Cardiac function and clinical status improved significantly over 3 months in responders, associated with a reduction in systolic dyssynchrony (Ts-SD-12 32.5 vs. 45.0 ms, P=0.003). The ‘dyssynchrony index’ (Ts-SD-12) was the only independent predictor of reverse remodelling, with a pre-implant cut-off of 32.6 ms (two SD from the mean of 88 normal controls) remarkably separating responders from non-responders completely.

In a similar prospective 3-month study involving 58 patients, greater clinical and volumetric improvements occurred in patients with wide compared with intermediate QRS durations.56 This related to a higher prevalence of intraventricular dyssynchrony in the wide QRS group, correlating closely with reverse remodelling (r=−0.78, P<0.001). The systolic ‘dyssynchrony index’ was again the only independent predictor of reverse remodelling, with a sensitivity of 94% and specificity of 83% using the predefined cut-off of 32.6 ms.

Recently, two further studies used TDI to predict responders. In the first, the only independent determinant of remodelling was a peak velocity difference (PVD) >110 ms, defined as the maximal difference in time to peak velocity between six basal segments.57 Although specificity was low (55%), this would be improved at the expense of sensitivity (97%) by increasing the threshold characterizing dyssynchrony. Comparison of six ventricular walls (Ts-6 and Ts-12)49,57 requires a much higher cut-off to identify dyssynchrony than 2- or 4-segment models.26,45 This supports the earlier observation that myocardial delay is distributed around the entire ventricle, suggesting optimal assessment of dyssynchrony requires inclusion of all six walls.

In the second study, Penicka et al.58 used pulsed wave TDI to measure maximal difference in EMD between three basal LV segments (septal, lateral, and posterior). Interventricular dyssynchrony (EMD LV-RV) was assessed by comparing the RV basal lateral segment to the most delayed LV segment, and added to intraventricular dyssynchrony for a combined index (sum asynchrony). The predictive value of TDI interventricular dyssynchrony was almost that of intraventricular assessment, unlike measurement of conventional IVMD in previous studies.37 More importantly, ‘sum asynchrony’ identified all but one responder, suggesting for the first time that combining both inter- and intra-ventricular assessments may improve patient selection.

Predicting response using SRI

Several studies have demonstrated improvement in strain parameters following CRT,41,59,60 but only two have examined their ability to predict response.42,61 In a comprehensive study comparing 18 parameters,42 all TDI measurements significantly predicted reverse remodelling after 3 months. While the two segment models correlated modestly with remodelling, the higher predictive value of basal Ts-6 and Ts-12 was identical (r=−0.60, P<0.001). However, Ts-SD-12 was again the most powerful, and only independent, predictor in both ischaemic and non-ischaemic patients (r=−0.74, P<0.001 overall). By contrast, all strain rate parameters failed to predict response. The superiority of TDI is unsurprising as translational motion, the inherent limitation, influences all segments equally and myocardial velocity rather than timing, thus having minimal impact on dispersion of timing within the ventricle.62

More recently, dyssynchrony was defined by the temporal difference in peak radial strain between the anteroseptal and posterior walls,61 as compared by Pitzalis et al. using M-mode. Baseline delay differed significantly between acute haemodynamic responders and non-responders (249 vs. 137 ms, P<0.005), predicting response with 95% sensitivity and 88% specificity using the 130 ms cut-off introduced by Pitzalis et al.25,37 Interestingly, changes in stroke volume immediately after CRT correlated strongly with baseline delay until 200 ms (r=0.93, P<0.0001), after which a plateau was observed, similar to the pattern observed by Bax et al.26 Obviously ventricular haemodynamic or volumetric improvement following CRT is limited, no matter the severity of dyssynchrony.

Predicting response using TSI

The same two groups predicted acute or longer term response after CRT using TSI.46,63 In 29 patients, ≥65 ms delay between the anteroseptum and posterior wall predicted acute response, defined by ≥15% increase in stroke volume, with 87% sensitivity and 100% specificity.63 However, no baseline TSI pattern predicted long-term reverse remodelling, which correlated poorly with early haemodynamic response.

In a more substantive study involving 56 patients, Yu et al.46 examined both qualitative visual TSI images and quantitative TSI parameters, comparing the latter with traditional TDI velocity data. Ts measurements by TSI and TDI velocity curves correlated very highly (r=0.97, P<0.001), validating the TSI software. Of all baseline TSI visual patterns, only severe lateral wall delay (coloured red) predicted reverse remodelling, with high specificity (89%) but low sensitivity (47%). All the quantitative TSI parameters were significantly higher in responders and correlated with volumetric changes (Table 7).

In contrast to their earlier study,42 parameters based on standard deviation or range yielded similar overall accuracy and correlations (r=0.52 vs. 0.53 and r=0.61 vs. 0.60) in both the 6- and 12-segment models respectively. This suggests the method of quantifying ‘spread’ is only of minor importance. Much emphasis was placed on the higher correlations and accuracy of the 12-segment compared to the 6-segment parameters. However, in the previous study Ts-6 and Ts-12 demonstrated identical correlations (r=0.60).42 Herein lies the Achilles heel of the dyssynchrony debate: minor differences in small patient groups are frequently over-interpreted, without statistical confidence that disparities are not simply the play of chance.

Cautions regarding responders and non-responders

Clinical responders

Clinical response is variably defined.3 The clinical composite score,64 used in the Multicentre InSync Randomized Clinical Evaluation (MIRACLE),2 classifies patients as improved, unchanged, or worsened. The score combines measures of functional status (NYHA class or moderate change in patient global assessment) with major adverse clinical outcomes (death, hospitalization) and withdrawal of study medication relating to worsening HF. However, different clinical composite endpoints in other studies limit comparisons, with components including transplantation,65 6 minute walking distance,24,26,57,65 peak oxygen consumption,24,27 and quality of life scores.57,66 Furthermore, clinical measures are subject to placebo effect: 39% of controls as well as 67% of the treatment group were responders in the MIRACLE study.2

Volumetric responders

A 15% reduction in LVESV is considered indicative of reverse remodelling (Table 7). In CRT studies, as with trials of drug therapy,67 the onset of remodelling often coincides with clinical improvement, in terms of NYHA class, exercise capacity, or quality of life score.25,26,37,45,55 Changes in cardiac size and function, quantified by LVESV and LVEF respectively, provide objective measures independent of placebo effect. However, definitions are arbitrary and magnitude of either response may not reach a specific threshold. Clinical response may occur without volumetric change or vice versa. Correlations between the two are weak.16 Clinical outcomes improve with CRT irrespective of HF aetiology.2,22,23 By contrast, echocardiographic reverse remodelling is significantly greater in patients with non-ischaemic compared with ischaemic cardiomyopathy.16,68 The discrepancy is also apparent in echocardiographic studies,26,57 in which TDI parameters predict clinical response less accurately than reverse remodelling (Table 7).

Non-responders

In around one-quarter to one-half of patients, clinical and volumetric non-responders are consistently observed, the latter being more frequent (Tables 2 and 7). The disparity between clinical and volumetric responses relates in part to arbitrary volumetric cut-offs and different parameters defining clinical response. This serves to highlight limitations in characterizing response and cautions against substituting remodelling for clinical efficacy. Moreover, failing to achieve selected ‘response’ criteria is not necessarily ‘non-response’. Without CRT, a patient may have undergone further adverse remodelling, been unable to achieve their current walking distance, or indeed be dead. A crucial weakness of echocardiographic studies is the absence of ‘hard’ endpoints—all cause mortality, cardiovascular death, and hospitalizations.

The PROSPECT study: predictors of response to CRT

The PROSPECT study is currently evaluating the ability of conventional and TDI parameters to predict a positive clinical and echocardiographic response in approximately 300 patients in up to 75 centres.36 Entry criteria include a QRS duration ≥130 ms, although centres outside the United States may enrol patients with a QRS duration <130 ms with echocardiographic evidence of dyssynchrony. Although larger-scale and a prospective study, PROSPECT is not enrolling sequential patients and suffers from the interpretative limitations alluded to above.

Reasons for non-response

Lack of response has been attributed to the absence of sufficient baseline dyssynchrony to allow improvement with therapy. However, no echocardiographic indicator of dyssynchrony will completely predict a successful response, given the numerous other potential reasons for non-response: suboptimal lead placement; non-viable ischaemic or infarcted myocardium;65,66,69 poor threshold or inadequate device optimization; severe LV dilatation;65 irreversible mitral annular dilatation and severe regurgitation;65 and development of atrial fibrillation after implantation. Most important of all, perhaps, is the duration of CRT. It is highly unlikely, for example, that β-blockers would have showed clear-cut clinical or volumetric benefits in similar small-scale and short-duration studies with the endpoints used.

Summary

Improving clinical outcomes is clearly desirable. However, current proposals that would deny patients an effective treatment with a Class I, Level A guideline recommendation are misguided, unique to devices (as opposed to drugs), and driven in part by limited healthcare budgets. Echocardiographic parameters of dyssynchrony are not robust enough to withhold CRT, with proven morbidity and mortality benefits, from patients. Landmark trials have randomized over 4000 patients based on their electrocardiogram as opposed to 92 by echocardiogram (in conjunction with a borderline QRS duration). Although PROSPECT is a fairly large study, it is observational and primarily serves to generate a hypothesis requiring validation in a prospective randomized trial, i.e. that treatment of patients selected on the basis of mechanical dyssynchrony with biventricular pacing will lead to improved morbidity and mortality.

Extending CRT to patients with narrow QRS complexes based on echocardiographic parameters is currently unfounded. Echocardiographic assessment will only become credible and applicable to clinical practice once used to select patients for large prospective randomized trials which show an improvement in clinical outcome. An obvious target population is patients with mechanical dyssynchrony but narrow QRS complexes. From existing evidence, contrary to recent opinion,4 we believe it neither mandatory to alter current guidelines for patient selection (to either restrict or expand the indication for CRT) nor essential to include echocardiographic assessment. For now, the cornerstone of dyssynchrony assessment remains the parameter prospectively validated in landmark clinical trials—the ECG-documented QRS duration.

Conflict of interest. The authors have no conflict of interest to declare regarding companies' manufacturing devices or echocardiography systems.

References

1
Swedberg
K
Cleland
J
Dargie
H
Drexler
H
Follath
F
Komajda
M
Tavazzi
L
Smiseth
OA
Gavazzi
A
Haverich
A
Hoes
A
Jaarsma
T
Korewicki
J
Levy
S
Linde
C
Lopez-Sendon
JL
Nieminen
MS
Pierard
L
Remme
WJ
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology
Eur Heart J
2005
, vol. 
26
 (pg. 
1115
-
1140
)
2
Abraham
WT
Fisher
WG
Smith
AL
DeLurgio
DB
Leon
AR
Loh
E
Kocovic
DZ
Packer
M
Clavell
AL
Hayes
DL
Ellestad
M
Trupp
RJ
Underwood
J
Pickering
F
Truex
C
McAtee
P
Messenger
J
Cardiac resynchronization in chronic heart failure
N Engl J Med
2002
, vol. 
346
 (pg. 
1845
-
1853
)
3
Yu
CM
Wing-Hong
FJ
Zhang
Q
Sanderson
JE
Understanding nonresponders of cardiac resynchronization therapy—current and future perspectives
J Cardiovasc Electrophysiol
2005
, vol. 
16
 (pg. 
1117
-
1124
)
4
Bax
JJ
Abraham
T
Barold
SS
Breithardt
OA
Fung
JW
Garrigue
S
Gorcsan
J
III
Hayes
DL
Kass
DA
Knuuti
J
Leclercq
C
Linde
C
Mark
DB
Monaghan
MJ
Nihoyannopoulos
P
Schalij
MJ
Stellbrink
C
Yu
CM
Cardiac resynchronization therapy. Part 1. Issues before device implantation
J Am Coll Cardiol
2005
, vol. 
46
 (pg. 
2153
-
2167
)
5
Shenkman
HJ
Pampati
V
Khandelwal
AK
McKinnon
J
Nori
D
Kaatz
S
Sandberg
KR
McCullough
PA
Congestive heart failure and QRS duration: establishing prognosis study
Chest
2002
, vol. 
122
 (pg. 
528
-
534
)
6
McCullough
PA
Hassan
SA
Pallekonda
V
Sandberg
KR
Nori
DB
Soman
SS
Bhatt
S
Hudson
MP
Weaver
WD
Bundle branch block patterns, age, renal dysfunction, and heart failure mortality
Int J Cardiol
2005
, vol. 
102
 (pg. 
303
-
308
)
7
Silvet
H
Amin
J
Padmanabhan
S
Pai
RG
Prognostic implications of increased QRS duration in patients with moderate and severe left ventricular systolic dysfunction
Am J Cardiol
2001
, vol. 
88
 (pg. 
182
-
185
)pg. 
A6
 
8
Baldasseroni
S
Opasich
C
Gorini
M
Lucci
D
Marchionni
N
Marini
M
Campana
C
Perini
G
Deorsola
A
Masotti
G
Tavazzi
L
Maggioni
AP
Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure
Am Heart J
2002
, vol. 
143
 (pg. 
398
-
405
)
9
Gottipaty
VK
Krelis
SP
Lu
F
Spencer
EP
Shusterman
V
Weiss
R
Brode
S
White
A
Anderson
KP
White
BG
Feldman
AM
The resting electrocardiogram provides a sensitive and inexpensive marker of prognosis in patients with chronic congestive heart failure
J Am Coll Cardiol
1999
, vol. 
33
 
A
pg. 
145A
 
10
Blanc
JJ
Etienne
Y
Gilard
M
Mansourati
J
Munier
S
Boschat
J
Benditt
DG
Lurie
KG
Evaluation of different ventricular pacing sites in patients with severe heart failure: results of an acute hemodynamic study
Circulation
1997
, vol. 
96
 (pg. 
3273
-
3277
)
11
Kass
DA
Chen
CH
Curry
C
Talbot
M
Berger
R
Fetics
B
Nevo
E
Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay
Circulation
1999
, vol. 
99
 (pg. 
1567
-
1573
)
12
Auricchio
A
Stellbrink
C
Block
M
Sack
S
Vogt
J
Bakker
P
Klein
H
Kramer
A
Ding
J
Salo
R
Tockman
B
Pochet
T
Spinelli
J
Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group
Circulation
1999
, vol. 
99
 (pg. 
2993
-
3001
)
13
Leclercq
C
Cazeau
S
Le Breton
H
Ritter
P
Mabo
P
Gras
D
Pavin
D
Lazarus
A
Daubert
JC
Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure
J Am Coll Cardiol
1998
, vol. 
32
 (pg. 
1825
-
1831
)
14
Breithardt
OA
Sinha
AM
Schwammenthal
E
Bidaoui
N
Markus
KU
Franke
A
Stellbrink
C
Acute effects of cardiac resynchronization therapy on functional mitral regurgitation in advanced systolic heart failure
J Am Coll Cardiol
2003
, vol. 
41
 (pg. 
765
-
770
)
15
Stellbrink
C
Breithardt
OA
Franke
A
Sack
S
Bakker
P
Auricchio
A
Pochet
T
Salo
R
Kramer
A
Spinelli
J
Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances
J Am Coll Cardiol
2001
, vol. 
38
 (pg. 
1957
-
1965
)
16
John Sutton
MG
Plappert
T
Abraham
WT
Smith
AL
DeLurgio
DB
Leon
AR
Loh
E
Kocovic
DZ
Fisher
WG
Ellestad
M
Messenger
J
Kruger
K
Hilpisch
KE
Hill
MR
Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure
Circulation
2003
, vol. 
107
 (pg. 
1985
-
1990
)
17
Saxon
LA
De Marco
T
Schafer
J
Chatterjee
K
Kumar
UN
Foster
E
Effects of long-term biventricular stimulation for resynchronization on echocardiographic measures of remodeling
Circulation
2002
, vol. 
105
 (pg. 
1304
-
1310
)
18
Lau
CP
Yu
CM
Chau
E
Fan
K
Tse
HF
Lee
K
Tang
MO
Wan
SH
Law
TC
Lee
PY
Lam
YM
Hill
MR
Reversal of left ventricular remodeling by synchronous biventricular pacing in heart failure
Pacing Clin Electrophysiol
2000
, vol. 
23
 (pg. 
1722
-
1725
)
19
Cazeau
S
Leclercq
C
Lavergne
T
Walker
S
Varma
C
Linde
C
Garrigue
S
Kappenberger
L
Haywood
GA
Santini
M
Bailleul
C
Daubert
JC
Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay
N Engl J Med
2001
, vol. 
344
 (pg. 
873
-
880
)
20
Auricchio
A
Kloss
M
Trautmann
SI
Rodner
S
Klein
H
Exercise performance following cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay
Am J Cardiol
2002
, vol. 
89
 (pg. 
198
-
203
)
21
Auricchio
A
Stellbrink
C
Sack
S
Block
M
Vogt
J
Bakker
P
Huth
C
Schondube
F
Wolfhard
U
Bocker
D
Krahnefeld
O
Kirkels
H
Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay
J Am Coll Cardiol
2002
, vol. 
39
 (pg. 
2026
-
2033
)
22
Bristow
MR
Saxon
LA
Boehmer
J
Krueger
S
Kass
DA
De Marco
T
Carson
P
DiCarlo
L
DeMets
D
White
BG
DeVries
DW
Feldman
AM
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure
N Engl J Med
2004
, vol. 
350
 (pg. 
2140
-
2150
)
23
Cleland
JG
Daubert
JC
Erdmann
E
Freemantle
N
Gras
D
Kappenberger
L
Tavazzi
L
The effect of cardiac resynchronization on morbidity and mortality in heart failure
N Engl J Med
2005
, vol. 
352
 (pg. 
1539
-
1549
)
24
Lecoq
G
Leclercq
C
Leray
E
Crocq
C
Alonso
C
de Place
C
Mabo
P
Daubert
C
Clinical and electrocardiographic predictors of a positive response to cardiac resynchronization therapy in advanced heart failure
Eur Heart J
2005
, vol. 
26
 (pg. 
1094
-
1100
)
25
Pitzalis
MV
Iacoviello
M
Romito
R
Guida
P
De Tommasi
E
Luzzi
G
Anaclerio
M
Forleo
C
Rizzon
P
Ventricular asynchrony predicts a better outcome in patients with chronic heart failure receiving cardiac resynchronization therapy
J Am Coll Cardiol
2005
, vol. 
45
 (pg. 
65
-
69
)
26
Bax
JJ
Bleeker
GB
Marwick
TH
Molhoek
SG
Boersma
E
Steendijk
P
Van der Wall
EE
Schalij
MJ
Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy
J Am Coll Cardiol
2004
, vol. 
44
 (pg. 
1834
-
1840
)
27
Alonso
C
Leclercq
C
Victor
F
Mansour
H
de Place
C
Pavin
D
Carre
F
Mabo
P
Daubert
JC
Electrocardiographic predictive factors of long-term clinical improvement with multisite biventricular pacing in advanced heart failure
Am J Cardiol
1999
, vol. 
84
 (pg. 
1417
-
1421
)
28
Auricchio
A
Yu
CM
Beyond the measurement of QRS complex toward mechanical dyssynchrony: cardiac resynchronisation therapy in heart failure patients with a normal QRS duration
Heart
2004
, vol. 
90
 (pg. 
479
-
481
)
29
Yu
CM
Yang
H
Lau
CP
Wang
Q
Wang
S
Lam
L
Sanderson
JE
Regional left ventricle mechanical asynchrony in patients with heart disease and normal QRS duration: implication for biventricular pacing therapy
Pacing Clin Electrophysiol
2003
, vol. 
26
 (pg. 
562
-
570
)
30
Turner
MS
Bleasdale
RA
Mumford
CE
Frenneaux
MP
Morris-Thurgood
JA
Left ventricular pacing improves haemodynamic variables in patients with heart failure with a normal QRS duration
Heart
2004
, vol. 
90
 (pg. 
502
-
505
)
31
Leclercq
C
Faris
O
Tunin
R
Johnson
J
Kato
R
Evans
F
Spinelli
J
Halperin
H
McVeigh
E
Kass
DA
Systolic improvement and mechanical resynchronization does not require electrical synchrony in the dilated failing heart with left bundle-branch block
Circulation
2002
, vol. 
106
 (pg. 
1760
-
1763
)
32
Cazeau
S
Bordachar
P
Jauvert
G
Lazarus
A
Alonso
C
Vandrell
MC
Mugica
J
Ritter
P
Echocardiographic modeling of cardiac dyssynchrony before and during multisite stimulation: a prospective study
Pacing Clin Electrophysiol
2003
, vol. 
26
 (pg. 
137
-
143
)
33
Bader
H
Garrigue
S
Lafitte
S
Reuter
S
Jais
P
Haissaguerre
M
Bonnet
J
Clementy
J
Roudaut
R
Intra-left ventricular electromechanical asynchrony: a new independent predictor of severe cardiac events in heart failure patients
J Am Coll Cardiol
2004
, vol. 
43
 (pg. 
248
-
256
)
34
Ghio
S
Constantin
C
Klersy
C
Serio
A
Fontana
A
Campana
C
Tavazzi
L
Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS duration
Eur Heart J
2004
, vol. 
25
 (pg. 
571
-
578
)
35
Cleland
JG
Daubert
JC
Erdmann
E
Freemantle
N
Gras
D
Kappenberger
L
Klein
W
Tavazzi
L
The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points
Eur J Heart Fail
2001
, vol. 
3
 (pg. 
481
-
489
)
36
Yu
CM
Abraham
WT
Bax
J
Chung
E
Fedewa
M
Ghio
S
Leclercq
C
Leon
AR
Merlino
J
Nihoyannopoulos
P
Notabartolo
D
Sun
JP
Tavazzi
L
Predictors of response to cardiac resynchronization therapy (PROSPECT)—study design
Am Heart J
2005
, vol. 
149
 (pg. 
600
-
605
)
37
Pitzalis
MV
Iacoviello
M
Romito
R
Massari
F
Rizzon
B
Luzzi
G
Guida
P
Andriani
A
Mastropasqua
F
Rizzon
P
Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony
J Am Coll Cardiol
2002
, vol. 
40
 (pg. 
1615
-
1622
)
38
Marcus
GM
Rose
E
Viloria
EM
Schafer
J
De Marco
T
Saxon
LA
Foster
E
Septal to posterior wall motion delay fails to predict reverse remodeling or clinical improvement in patients undergoing cardiac resynchronization therapy
J Am Coll Cardiol
2005
, vol. 
46
 (pg. 
2208
-
2214
)
39
D'hooge
J
Heimdal
A
Jamal
F
Kukulski
T
Bijnens
B
Rademakers
F
Hatle
L
Suetens
P
Sutherland
GR
Regional strain and strain rate measurements by cardiac ultrasound: principles, implementation and limitations
Eur J Echocardiogr
2000
, vol. 
1
 (pg. 
154
-
170
)
40
Pislaru
C
Abraham
TP
Belohlavek
M
Strain and strain rate echocardiography
Curr Opin Cardiol
2002
, vol. 
17
 (pg. 
443
-
454
)
41
Popovic
ZB
Grimm
RA
Perlic
G
Chinchoy
E
Geraci
M
Sun
JP
Donal
E
Xu
XF
Greenberg
NL
Wilkoff
BL
Thomas
JD
Noninvasive assessment of cardiac resynchronization therapy for congestive heart failure using myocardial strain and left ventricular peak power as parameters of myocardial synchrony and function
J Cardiovasc Electrophysiol
2002
, vol. 
13
 (pg. 
1203
-
1208
)
42
Yu
CM
Fung
JW
Zhang
Q
Chan
CK
Chan
YS
Lin
H
Kum
LC
Kong
SL
Zhang
Y
Sanderson
JE
Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening on the prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac resynchronization therapy
Circulation
2004
, vol. 
110
 (pg. 
66
-
73
)
43
Sogaard
P
Kim
WY
Jensen
HK
Mortensen
P
Pedersen
AK
Kristensen
BO
Egeblad
H
Impact of acute biventricular pacing on left ventricular performance and volumes in patients with severe heart failure. A tissue Doppler and three-dimensional echocardiographic study
Cardiology
2001
, vol. 
95
 (pg. 
173
-
182
)
44
Sogaard
P
Egeblad
H
Kim
WY
Jensen
HK
Pedersen
AK
Kristensen
BO
Mortensen
PT
Tissue Doppler imaging predicts improved systolic performance and reversed left ventricular remodeling during long-term cardiac resynchronization therapy
J Am Coll Cardiol
2002
, vol. 
40
 (pg. 
723
-
730
)
45
Bax
JJ
Marwick
TH
Molhoek
SG
Bleeker
GB
van Erven
L
Boersma
E
Steendijk
P
Van der Wall
EE
Schalij
MJ
Left ventricular dyssynchrony predicts benefit of cardiac resynchronization therapy in patients with end-stage heart failure before pacemaker implantation
Am J Cardiol
2003
, vol. 
92
 (pg. 
1238
-
1240
)
46
Yu
CM
Zhang
Q
Fung
JW
Chan
HC
Chan
YS
Yip
GW
Kong
SL
Lin
H
Zhang
Y
Sanderson
JE
A novel tool to assess systolic asynchrony and identify responders of cardiac resynchronization therapy by tissue synchronization imaging
J Am Coll Cardiol
2005
, vol. 
45
 (pg. 
677
-
684
)
47
Ansalone
G
Giannantoni
P
Ricci
R
Trambaiolo
P
Fedele
F
Santini
M
Doppler myocardial imaging to evaluate the effectiveness of pacing sites in patients receiving biventricular pacing
J Am Coll Cardiol
2002
, vol. 
39
 (pg. 
489
-
499
)
48
Bleeker
GB
Schalij
MJ
Molhoek
SG
Verwey
HF
Holman
ER
Boersma
E
Steendijk
P
Van der Wall
EE
Bax
JJ
Relationship between QRS duration and left ventricular dyssynchrony in patients with end-stage heart failure
J Cardiovasc Electrophysiol
2004
, vol. 
15
 (pg. 
544
-
549
)
49
Yu
CM
Lin
H
Zhang
Q
Sanderson
JE
High prevalence of left ventricular systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration
Heart
2003
, vol. 
89
 (pg. 
54
-
60
)
50
Bleeker
GB
Schalij
MJ
Molhoek
SG
Holman
ER
Verwey
HF
Steendijk
P
Van der Wall
EE
Bax
JJ
Frequency of left ventricular dyssynchrony in patients with heart failure and a narrow QRS complex
Am J Cardiol
2005
, vol. 
95
 (pg. 
140
-
142
)
51
Rouleau
F
Merheb
M
Geffroy
S
Berthelot
J
Chaleil
D
Dupuis
JM
Victor
J
Geslin
P
Echocardiographic assessment of the interventricular delay of activation and correlation to the QRS width in dilated cardiomyopathy
Pacing Clin Electrophysiol
2001
, vol. 
24
 (pg. 
1500
-
1506
)
52
Bax
JJ
Molhoek
SG
van Erven
L
Voogd
PJ
Somer
S
Boersma
E
Steendijk
P
Schalij
MJ
Van der Wall
EE
Usefulness of myocardial tissue Doppler echocardiography to evaluate left ventricular dyssynchrony before and after biventricular pacing in patients with idiopathic dilated cardiomyopathy
Am J Cardiol
2003
, vol. 
91
 (pg. 
94
-
97
)
53
Yu
CM
Chau
E
Sanderson
JE
Fan
K
Tang
MO
Fung
WH
Lin
H
Kong
SL
Lam
YM
Hill
MR
Lau
CP
Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure
Circulation
2002
, vol. 
105
 
4
(pg. 
438
-
445
)
54
Yu
CM
Lin
H
Fung
WH
Zhang
Q
Kong
SL
Sanderson
JE
Comparison of acute changes in left ventricular volume, systolic and diastolic functions, and intraventricular synchronicity after biventricular and right ventricular pacing for heart failure
Am Heart J
2003
, vol. 
145
 pg. 
E18
 
55
Yu
CM
Fung
WH
Lin
H
Zhang
Q
Sanderson
JE
Lau
CP
Predictors of left ventricular reverse remodeling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy
Am J Cardiol
2003
, vol. 
91
 (pg. 
684
-
688
)
56
Yu
CM
Fung
JW
Chan
CK
Chan
YS
Zhang
Q
Lin
H
Yip
GW
Kum
LC
Kong
SL
Zhang
Y
Sanderson
JE
Comparison of efficacy of reverse remodeling and clinical improvement for relatively narrow and wide QRS complexes after cardiac resynchronization therapy for heart failure
J Cardiovasc Electrophysiol
2004
, vol. 
15
 (pg. 
1058
-
1065
)
57
Notabartolo
D
Merlino
JD
Smith
AL
DeLurgio
DB
Vera
FV
Easley
KA
Martin
RP
Leon
AR
Usefulness of the peak velocity difference by tissue Doppler imaging technique as an effective predictor of response to cardiac resynchronization therapy
Am J Cardiol
2004
, vol. 
94
 (pg. 
817
-
820
)
58
Penicka
M
Bartunek
J
De Bruyne
B
Vanderheyden
M
Goethals
M
De Zutter
M
Brugada
P
Geelen
P
Improvement of left ventricular function after cardiac resynchronization therapy is predicted by tissue Doppler imaging echocardiography
Circulation
2004
, vol. 
109
 (pg. 
978
-
983
)
59
Breithardt
OA
Stellbrink
C
Herbots
L
Claus
P
Sinha
AM
Bijnens
B
Hanrath
P
Sutherland
GR
Cardiac resynchronization therapy can reverse abnormal myocardial strain distribution in patients with heart failure and left bundle branch block
J Am Coll Cardiol
2003
, vol. 
42
 (pg. 
486
-
494
)
60
Sun
JP
Chinchoy
E
Donal
E
Popovic
ZB
Perlic
G
Asher
CR
Greenberg
NL
Grimm
RA
Wilkoff
BL
Thomas
JD
Evaluation of ventricular synchrony using novel Doppler echocardiographic indices in patients with heart failure receiving cardiac resynchronization therapy
J Am Soc Echocardiogr
2004
, vol. 
17
 (pg. 
845
-
850
)
61
Dohi
K
Suffoletto
MS
Schwartzman
D
Ganz
L
Pinsky
MR
Gorcsan
J
III
Utility of echocardiographic radial strain imaging to quantify left ventricular dyssynchrony and predict acute response to cardiac resynchronization therapy
Am J Cardiol
2005
, vol. 
96
 (pg. 
112
-
116
)
62
Weidemann
F
Bijnens
B
Strotmann
JM
Letter regarding article by Yu et al. Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening on the prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac resynchronization therapy
Circulation
2004
, vol. 
110
 (pg. 
e498
-
e499
)
63
Gorcsan
J
III
Kanzaki
H
Bazaz
R
Dohi
K
Schwartzman
D
Usefulness of echocardiographic tissue synchronization imaging to predict acute response to cardiac resynchronization therapy
Am J Cardiol
2004
, vol. 
93
 (pg. 
1178
-
1181
)
64
Packer
M
Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure
J Card Fail
2001
, vol. 
7
 (pg. 
176
-
182
)
65
Diaz-Infante
E
Mont
L
Leal
J
Garcia-Bolao
I
Fernandez-Lozano
I
Hernandez-Madrid
A
Perez-Castellano
N
Sitges
M
Pavon-Jimenez
R
Barba
J
Cavero
MA
Moya
JL
Perez-Isla
L
Brugada
J
Predictors of lack of response to resynchronization therapy
Am J Cardiol
2005
, vol. 
95
 (pg. 
1436
-
1440
)
66
Reuter
S
Garrigue
S
Barold
SS
Jais
P
Hocini
M
Haissaguerre
M
Clementy
J
Comparison of characteristics in responders versus nonresponders with biventricular pacing for drug-resistant congestive heart failure
Am J Cardiol
2002
, vol. 
89
 (pg. 
346
-
350
)
67
Bristow
MR
Gilbert
EM
Abraham
WT
Adams
KF
Fowler
MB
Hershberger
RE
Kubo
SH
Narahara
KA
Ingersoll
H
Krueger
S
Young
S
Shusterman
N
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators
Circulation
1996
, vol. 
94
 (pg. 
2807
-
2816
)
68
Duncan
A
Wait
D
Gibson
D
Daubert
JC
Left ventricular remodelling and haemodynamic effects of multisite biventricular pacing in patients with left ventricular systolic dysfunction and activation disturbances in sinus rhythm: sub-study of the MUSTIC (Multisite Stimulationin Cardiomyopathies) trial
Eur Heart J
2003
, vol. 
24
 (pg. 
430
-
441
)
69
Gasparini
M
Mantica
M
Galimberti
P
Genovese
L
Pini
D
Faletra
F
Marchesina
UL
Mangiavacchi
M
Klersy
C
Gronda
E
Is the outcome of cardiac resynchronization therapy related to the underlying etiology?
Pacing Clin Electrophysiol
2003
, vol. 
26
 (pg. 
175
-
180
)
70
Auricchio
A
Stellbrink
C
Butter
C
Sack
S
Vogt
J
Misier
AR
Bocker
D
Block
M
Kirkels
JH
Kramer
A
Huvelle
E
Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay
J Am Coll Cardiol
2003
, vol. 
42
 (pg. 
2109
-
2116
)
71
Leclercq
C
Walker
S
Linde
C
Clementy
J
Marshall
AJ
Ritter
P
Djiane
P
Mabo
P
Levy
T
Gadler
F
Bailleul
C
Daubert
JC
Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation
Eur Heart J
2002
, vol. 
23
 (pg. 
1780
-
1787
)
72
Young
JB
Abraham
WT
Smith
AL
Leon
AR
Lieberman
R
Wilkoff
B
Canby
RC
Schroeder
JS
Liem
LB
Hall
S
Wheelan
K
Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial
J Am Med Assoc
2003
, vol. 
289
 (pg. 
2685
-
2694
)
73
Abraham
WT
Young
JB
Leon
AR
Adler
S
Bank
AJ
Hall
SA
Lieberman
R
Liem
LB
O'Connell
JB
Schroeder
JS
Wheelan
KR
Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure
Circulation
2004
, vol. 
110
 (pg. 
2864
-
2868
)
74
Higgins
SL
Hummel
JD
Niazi
IK
Giudici
MC
Worley
SJ
Saxon
LA
Boehmer
JP
Higginbotham
MB
De Marco
T
Foster
E
Yong
PG
Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias
J Am Coll Cardiol
2003
, vol. 
42
 (pg. 
1454
-
1459
)
75
Molhoek
SG
van Erven
L
Bootsma
M
Steendijk
P
Van Der Wall
EE
Schalij
MJ
QRS duration and shortening to predict clinical response to cardiac resynchronization therapy in patients with end-stage heart failure
Pacing Clin Electrophysiol
2004
, vol. 
27
 (pg. 
308
-
313
)